Doximity, Inc. (NYSE:DOCS – Get Free Report) insider Siddharth Sitaram sold 2,444 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $20.41, for a total value of $49,882.04. Following the sale, the insider owned 90,706 shares in the company, valued at $1,851,309.46. This trade represents a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Siddharth Sitaram also recently made the following trade(s):
- On Monday, May 11th, Siddharth Sitaram sold 2,309 shares of Doximity stock. The shares were sold at an average price of $25.77, for a total value of $59,502.93.
- On Friday, April 10th, Siddharth Sitaram sold 2,427 shares of Doximity stock. The shares were sold at an average price of $21.09, for a total value of $51,185.43.
Doximity Price Performance
NYSE:DOCS opened at $20.24 on Thursday. Doximity, Inc. has a 52 week low of $17.15 and a 52 week high of $76.51. The firm has a market cap of $3.70 billion, a PE ratio of 20.45, a PEG ratio of 3.48 and a beta of 1.30. The company’s 50-day simple moving average is $22.42.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several research firms have commented on DOCS. Piper Sandler boosted their price objective on Doximity from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Robert W. Baird reiterated a “neutral” rating and set a $18.00 price objective (down from $40.00) on shares of Doximity in a research note on Thursday, May 14th. Weiss Ratings lowered Doximity from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 15th. JPMorgan Chase & Co. cut their price objective on Doximity from $33.00 to $28.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Finally, Mizuho cut their price objective on Doximity from $34.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $30.62.
Get Our Latest Stock Report on Doximity
Doximity Company Profile
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
Featured Stories
- Five stocks we like better than Doximity
- The “Duck Stock” Keeps Quietly Making Money for Shareholders
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
